Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dabrafenib Receives Breakthrough Designation for NSCLC

January 13th 2014

The BRAF inhibitor dabrafenib (Tafinlar) has received a Breakthrough Therapy designation from the FDA for its potential as a treatment for patients with metastatic BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing chemotherapy.

Dr. Kris on the Challenges of Treating Lung Cancer

January 13th 2014

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses some of the challenges of treating patients with lung cancer.

"N of 1" Research: Molecular Findings Create Urgency for New Drug Discovery Paradigm

January 13th 2014

There has been considerable discussion within the oncology literature during the past several years regarding the level of evidence required to consider a new antineoplastic agent an acceptable "standard-of-care" in routine disease management.

Dr. Shaw on Crizotinib as a Standard of Care in NSCLC

January 9th 2014

Alice T. Shaw, MD, PhD, discusses how crizotinib has changed patient care over the last few years.

Dr. Rizvi on Pseudo-Progression in Lung Cancer

January 6th 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Making Sense of the USPSTF Recommendations on Lung Cancer Screening

January 2nd 2014

On December 30th, the United States Preventive Services Task Force (USPSTF) announced they recommend annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55-80 years who have a 30 pack-year smoking history.

Model Emerges for Targeting Oncogenes in NSCLC

December 30th 2013

Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of non-small cell lung cancer, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of anaplastic lymphoma kinase.

Dr. Belani Discusses Treating NSCLC with CO-1686

December 6th 2013

Chandra P. Belani, MD, discusses CO-1686, which is currently being studied for the treatment of non-small cell lung cancer.

Dr. Herbst on PD-1 Inhibitors in Lung Cancer

November 26th 2013

Roy S. Herbst, MD, PhD, discusses the sequencing possibilities of anti-PD-1 agents in treating patients with lung cancer.

Dr. Piperdi on the Stimuvax Vaccine in Lung Cancer

November 20th 2013

Bilal Piperdi, MD, from the Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

Dr. Mark G. Kris on the Future of Lung Cancer

November 19th 2013

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the future of lung cancer treatment at the 8th Annual New York Lung Cancer Symposium®

Individualized Treatment for Non-Small Cell Lung Cancer

November 15th 2013

Drug research and development continues to focus on regimens that select therapy according to the pathologic and molecular characteristics of the tumor.

PD-1 and PD-L1 Inhibitors Expected to 'Change the Landscape' of Lung Cancer Treatment

November 11th 2013

The future of PD-1 and PD-L1 inhibition in non-small cell lung cancer is bright, with ongoing studies suggesting that the strategy will lead to a 'new world' in the treatment of the disease

Next Generation ALK Inhibitors Poised to Become Standard of Care for Crizotinib-Resistant Patients

November 11th 2013

Next-generation ALK inhibitors are being developed to address the unmet need of patients with non-small cell lung cancer who are becoming resistant to crizotinib.

Targeted Therapies Explored in Small Cell Lung Cancer

November 11th 2013

While targeted and immunotherapy drugs have recently shown promise in non-small cell lung cancer (NSCLC), similar developments in small cell lung cancer (SCLC) have not materialized.

Dr. Rizvi on PD-1 and PD-L1 Inhibitors in Lung Cancer

November 10th 2013

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Dr. Shaw on Monitoring Crizotinib-Related Side Effects

November 10th 2013

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses monitoring adverse events associated with crizotinib when treating patients with ALK-positive lung cancer

NY Symposium Tackles Emerging Agents, Pressing Questions in Lung Cancer

November 8th 2013

Leaders in thoracic medical oncology from major cancer centers will come together Saturday to discuss advances in the field of lung cancer treatment during the 8th Annual New York Lung Cancer Symposium® in New York City.

Dr. Paul Bunn on TKIs in Advanced Lung Cancer

November 4th 2013

Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, explains how patients with advanced-stage lung cancer benefit from tyrosine kinase inhibitors

ALK-Positive Criteria for Determining Crizotinib Use May Fall Short

November 4th 2013

The criteria that are presently used to determine whether patients with non-small cell lung cancer may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug.